|1.||Liu, Shuang: 21 articles (08/2015 - 09/2006)|
|2.||Chen, Xiaoyuan: 17 articles (09/2012 - 01/2004)|
|3.||Kim, Young-Seung: 10 articles (03/2012 - 03/2007)|
|4.||Shi, Jiyun: 8 articles (10/2011 - 12/2008)|
|5.||Zhou, Yang: 7 articles (09/2013 - 01/2011)|
|6.||Wang, Fan: 7 articles (01/2011 - 03/2007)|
|7.||Kataoka, Kazunori: 6 articles (12/2015 - 09/2007)|
|8.||Chakraborty, Sudipta: 6 articles (10/2013 - 08/2009)|
|9.||Matsumoto, Yu: 5 articles (12/2015 - 06/2012)|
|10.||Nishiyama, Nobuhiro: 5 articles (12/2015 - 09/2007)|
09/01/2012 - "In this study, we labeled a PEGylated cyclic RGD peptide dimer, PEG(3)-E[c(RGDyK)](2) (PRGD2), using [(18)F]SFMB and evaluated for imaging tumor αvβ3 integrin expression with positron emission tomography (PET). "
08/02/2010 - "Incorporation of biologically active cRGD peptide on the surface of nanoparticles was confirmed by in vitro cell uptake studies and in vivo tumor accumulation studies. "
02/01/2015 - "Cyclic RGD peptide, used as a tumor targeting ligand, was then selectively conjugated onto the distal ends of the PEG arms. "
01/01/2015 - "Hence, cyclic RGD conjugation makes the GNP-based radiosensitizer tumor targeting, offering a new modality for enhancing radiotherapeutic efficacy. "
06/01/2014 - "Treatment with cyclic-RGD-PLGC(Me)AG-MMAE-ACPP resulted in complete tumor regression in one quarter of MDA-MB-231 tumor-bearing mice, compared with no survival in the control groups. "
|2.||Breast Neoplasms (Breast Cancer)
03/01/2007 - "Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer."
02/01/2015 - "In this study two (111)In-labeled dimeric cyclic RGD peptides, (111)In(DOTA-Galacto-RGD2) and (111)In(DOTA-3P-RGD2), were evaluated as radiotracers for breast tumor imaging. "
01/01/2011 - "The purpose of this study was the assessment of the feasibility of dynamic positron emission tomography (PET) studies with fluorine-18 fluorodeoxyglucose ((18)F-FDG) to quantify effects of the cyclic Arg-Gly-Asp peptide cilengitide, which targets the ανβ 3 and ανβ 5 integrin receptors in rats with breast cancer bone metastases. "
08/01/2002 - "This study was designed to determine whether, and how, the cyclic Arg-Gly-Asp peptide Cilengitide (EMD 121974), which targets the alpha(v)beta(3) integrin receptor expressed on neovasculature, could increase systemic RIT efficacy of therapy in a human breast cancer tumor model having mutant p53 and expressing bcl-2. "
01/01/2009 - "This report describes the synthesis of two cyclic RGD (Arg-Gly-Asp) conjugates, HYNIC-2PEG(4)-dimer (HYNIC = 6-hydrazinonicotinyl; 2PEG(4)-dimer = E[PEG(4)-c(RGDfK)](2); and PEG(4) = 15-amino-4,7,10,13-tetraoxapentadecanoic acid) and HYNIC-3PEG(4)-dimer (3PEG(4)-dimer = PEG(4)-E[PEG(4)-c(RGDfK)](2)), and evaluation of their (99m)Tc complexes [(99m)Tc(HYNIC-2PEG(4)-dimer)(tricine)(TPPTS)] ((99m)Tc-2PEG(4)-dimer: TPPTS = trisodium triphenylphosphine-3,3',3''-trisulfonate) and [(99m)Tc(HYNIC-3PEG(4)-dimer)(tricine)(TPPTS)] ((99m)Tc-3PEG(4)-dimer) as novel radiotracers for imaging integrin alpha(v)beta(3) expression in athymic nude mice bearing U87MG glioma and MDA-MB-435 breast cancer xenografts. "
|3.||Neoplasm Metastasis (Metastasis)
03/04/2002 - "Furthermore, growth and metastasis of subcutaneous tumours after administration of the cyclic RGD-peptide was significantly delayed in comparison to controls (P<0.05). "
05/31/1991 - "Effect of cyclic RGD peptide on cell adhesion and tumor metastasis."
03/04/2002 - "The aim of this study was to investigate the effects of application of a methylated cyclic RGD-peptide as an alpha(v)-integrin antagonist on angiogenesis, microcirculation, growth and metastasis formation of a solid tumour in vivo. "
03/04/2002 - "Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo."
01/01/2011 - "Results indicated that cyclic RGD peptide-anchored sterically stabilized nanospheres bearing fluorouracil were significantly (P ≤ 0.01) active against primary tumour and metastasis than the nontargeted sterically stabilized nanospheres and free drug. "
01/01/2006 - "Our previous in vitro studies using atomic force microscopy measurement of monocyte-endothelial cell interaction have demonstrated that a cyclic arginine-glycine-aspartic acid peptide (cRGD) inhibited their adhesion through very late antigen (alpha4beta1-integrin; VLA4)-vascular cell adhesion molecule-1 by 60% with the IC50 = 100 nM. To elucidate the potential efficacy of this peptide in vivo in preventing atherogenesis, experiments were performed in apolipoprotein E (ApoE)-deficient (-/-) mice fed a Western diet and receiving chronic treatment with cRGD peptide for 2-4 wk. In addition, some animals were subjected to a temporary carotid artery ligation while receiving the above treatment. "
|5.||Glioblastoma (Glioblastoma Multiforme)
01/14/2015 - "After conjugation with a cyclic RGD peptide they selectively targeted integrin αvβ3 receptors on glioblastoma cells with high internalization efficacy. "
03/26/2014 - "The Si-HPG has been transformed into cyclic RGD peptide functionalized nanoprobe using the conventional bioconjugation chemistry and used for specific targeting to αvβ3 integrin overexpressed cervical cancer cells and glioblastoma cells. "
08/10/2010 - "When encapsulated in liposomes decorated with an integrin-targeting cyclic-RGD peptide, however, (D)PMI-alpha exerted potent p53-dependent growth inhibitory activity against human glioblastoma in cell cultures and nude mouse xenograft models. "
12/01/2010 - "Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors. "
01/02/2012 - "Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery."
|1.||cyclic arginine-glycine-aspartic acid peptide
|5.||Integrin beta3 (GPIIIa)
|6.||Integrin alpha4beta1 (VLA-4)
|7.||Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)
|8.||Apolipoproteins E (ApoE)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Quantum Dots (Quantum Dot)